KRAS and cancer: To this end, we compared compound-proteome interaction signatures to compounds that are known to be effective against particular mutants of KRAS, which were then used to generate novel predictions of compounds and synergies that may be effective against KRAS-mutant driven cancers and validated (Figure 2).